Q1 25 EPS
$3.34
MISS 3.39%
Est. $3.46
Q1 25 Revenue
$12.73B
BEAT +0.05%
Est. $12.72B
vs S&P Since Q1 25
-11.9%
TRAILING MARKET
LLY +17.1% vs S&P +29.0%
Market Reaction
Did LLY Beat Earnings? Q1 2025 Results
Eli Lilly posted a headline-grabbing first quarter for 2025, with revenue climbing 45.2% year-over-year to $12.73 billion, edging just past the $12.72 billion consensus, yet earnings per share of $3.34 fell short of the $3.46 analyst estimate by 3.39… Read more Eli Lilly posted a headline-grabbing first quarter for 2025, with revenue climbing 45.2% year-over-year to $12.73 billion, edging just past the $12.72 billion consensus, yet earnings per share of $3.34 fell short of the $3.46 analyst estimate by 3.39%, weighed down by $1.57 billion in acquired in-process research and development charges tied to its acquisition of Scorpion Therapeutics' PI3Kα inhibitor program, which alone depressed EPS by $1.72. The growth engine remained tirzepatide in its two approved forms, with Mounjaro revenue more than doubling to $3.84 billion and Zepbound generating $2.31 billion in U.S. Revenue, together accounting for the overwhelming majority of the company's expansion. Lilly reaffirmed its full-year 2025 revenue guidance of $58.00 billion to $61.00 billion, though it trimmed EPS guidance to $20.17 to $21.67 on a reported basis, reflecting those IPR&D charges. In a broader industry context, Lilly also pledged to exceed $50 billion in U.S. Manufacturing investment since 2020, joining peers in expanding domestic production capacity ahead of potential pharmaceutical sector tariffs.
Key Takeaways
- • 53% increase in volume driving 45% revenue growth
- • Strong Mounjaro demand with 113% revenue growth worldwide
- • Zepbound U.S. revenue growth driven by increased demand
- • Gross margin improvement from better cost of production and favorable product mix
- • Jardiance one-time $370 million benefit from Boehringer Ingelheim collaboration amendment
LLY YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
LLY Revenue by Segment
With YoY comparisons, source: SEC Filings
LLY Revenue by Geography
With YoY comparisons, source: SEC Filings
“Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound. Our pipeline continued to deliver across key therapeutic areas, with product approvals in oncology and immunology, and the exciting success of our oral incretin, orforglipron, in the first of seven late-stage studies in diabetes and obesity. To support global demand for our newest medicines, we're accelerating our manufacturing investments, as underscored by our recent announcement to build four new facilities.”
— David A. Ricks, Q1 2025 Earnings Press Release
LLY Earnings Trends
LLY vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
LLY EPS Trend
Earnings per share: estimate vs actual
LLY Revenue Trend
Quarterly revenue: estimate vs actual
LLY Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $8.55 | — | $19.80B | +11.25% |
| Q4 25 BEAT FY | $7.17 | $7.54 | +5.16% | $19.29B | +7.33% |
| FY Full Year | $23.62 | $24.21 | +2.48% | $65.18B | +2.06% |
| Q3 25 BEAT | $5.89 | $7.02 | +19.15% | $17.60B | +9.53% |
| Q2 25 BEAT | $5.59 | $6.31 | +12.89% | $15.56B | +6.06% |
| Q1 25 MISS | $3.46 | $3.34 | -3.39% | $12.73B | +0.05% |